Hepatocellular carcinoma: an update.
نویسندگان
چکیده
Hepatocellular carcinoma is one of the most common malignant tumors worldwide. The major etiologies and risk factors for HCC development are well-defined and some of the multiple steps involved in hepatocarcinogenesis have been elucidated in recent years. Despite these scientific advances and the implementation of measures for early hepatocellular carcinoma detection in patients at risk, patient survival has not yet significantly improved during the last three decades. This is in part due to the advanced stage of the disease at the time of diagnosis, and in part due to the limited therapeutic options. These fall into five main categories: 1) surgical interventions, including liver transplantation; 2) percutaneous interventions, including ethanol injection and radiofrequency thermal ablation; 3) transarterial interventions; 4) radiation therapy; and 5) drugs as well as gene and immune therapies. While surgery and percutaneous as well as transarterial interventions are effective in patients with limited disease (1-3 lesions, <5 cm in diameter) and compensated underlying liver disease (cirrhosis Child A), at the time of diagnosis, more than 80% of patients present with multicentric hepatocellular carcinoma and advanced liver disease or comorbidities that restrict the therapeutic measures to best supportive care. Therefore, early diagnosis, the development of novel systemic therapies for advanced disease and hepatocellular carcinoma prevention are of paramount importance. New technologies, including gene expression profiling and proteomic analyses, should allow to further elucidate the molecular events underlying hepatocellular carcinoma development and to identify novel diagnostic markers as well as therapeutic and preventive targets.
منابع مشابه
DISCRIMINATION OF HEPATOCELLULAR CARCINOMA FROM CIRRHOTIC NODULES BY AgNOR STAIN
Discrimination of regenerative cirrhotic nodules of the liver (CN) from hepatocellular carcinoma (HCC) is sometimes difficult. We examined the utility of AgNOR staining in this context. Fifteen cases of HCC and 25 cases of CN were stained by AgNOR method and the mean AgNOR number for one hundred nuclei in each case was determined. There was a significant difference between the mean AgNOR c...
متن کاملIn Vitro Challenge using Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line
Black seed (Nigella sativa) is considered as a biological response modifier. Thymoquinone (TQ) is the bioactive and the most abundant constituent of the volatile oil of this seed which has been shown to possess anti-inflammatory, antioxidant and anti-neoplastic effects. In this study, the effect of TQ on HepG2 cell line was investigated in an attempt to identify its potential mechanism of actio...
متن کاملEffects of aqueous saffron extract on nitric oxide production by two human carcinoma cell lines: Hepatocellular carcinoma (HepG2) and laryngeal carcinoma (Hep2)
Objective: A number of studies have demonstrated the potential antitumor effects of saffron and its constituents on different malignant cells in vitro. It has been reported that a novel glycoconjugate isolated from corms and callus of saffron possesses cytotoxic activity against different tumor cellswith nitric oxide (NO) production. These data suggest that the cytotoxic effect of saffron extra...
متن کاملIn Vitro Challenge using Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line
Black seed (Nigella sativa) is considered as a biological response modifier. Thymoquinone (TQ) is the bioactive and the most abundant constituent of the volatile oil of this seed which has been shown to possess anti-inflammatory, antioxidant and anti-neoplastic effects. In this study, the effect of TQ on HepG2 cell line was investigated in an attempt to identify its potential mechanism of actio...
متن کاملEvaluation of serum AFP (α-fetoprotein) level in HBsAg carrier patients for diagnosis of hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is common all over the world as well as Iran. The incidence of HCC is higher in hepatitis B carriers and it is highly recommended to periodically screen these patients by serum alpha-fetoprotein (AFP) and liver ultrasound (US) every 6 months. We explore the diagnostic accuracy and the performance of (AFP) in cases of hepatitis B carriers as a scree...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Archives of Iranian medicine
دوره 10 3 شماره
صفحات -
تاریخ انتشار 2007